On top of noninferior efficacy, the trial showed patients had less bleeding with 2.5 mg vs 5.0 mg twice daily over 12 months.
CHICAGO, IL—For patients with active cancer who’ve had venous thromboembolism (VTE), 12-month extended anticoagulation with reduced-dose apixaban is noninferior to the full dose at preventing recurrent VTE, according to data from the API-CAT trial.
The lower dose of 2.5 mg twice daily also resulted in fewer clinically relevant bleeding complications than the 5.0-mg twice-daily dose, researchers report. The findings were presented Saturday at the American College of Cardiology (ACC) 2025 Scientific Session and simultaneously published in the New England Journal of Medicine.
Lead author Isabelle Mahé, MD, PhD (Assistance Publique–Hôpitaux de Paris, Université Paris Cité,…